Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 81-100 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 81 | Atomic-6 lowweak | Opp 4 Risk 5 | Thesis: Atomic-6 appears to have meaningful strategic upside because the membership rationale says it launched an orbital data center service and has DoD and U.S. Space Force contracts, which would support a long-duration defense/space infrastructure thesis if confirmed. Why now: The reviewed sources rationale cites article and says Atomic-6 launched an orbital data center service and has DoD and U.S. Space Force contracts, but no representative article or is provided in the visible reviewed sources, so timing confidence is limited. Caveats: No direct evidence or article are available in the reviewed sources body. Opportunity thesis relies on membership rationale rather than citable article summary. Because the underlying evidence is not exposed, conviction must stay low. |
| 82 | Beijing Guodian High-Tech Technology Co lowweak | Opp 4 Risk 2 | Thesis: Reviewed evidence rationale says the company received approval for a commercial satellite IoT pilot program using the Tianqi constellation of 41 satellites. Regulatory or pilot approval tied to an existing constellation is a meaningful long-horizon opportunity signal if execution follows. Why now: The implied catalyst is the pilot-program approval, but the reviewed sources provide no retained article summary or timestamped evidence row beyond the membership rationale. Caveats: Phase2 membership rationale references: but the actual summary/evidence are absent. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score is restrained because approval alone is described in rationale but not directly evidenced here. |
| 83 | D-Orbit lowweak | Opp 4 Risk 3 | Thesis: Moderate evidence-ranked opportunity: the reviewed sources membership rationale says D-Orbit partnered with Magdrive for an electric propulsion demo and places the company in satellite propulsion/orbital logistics, which suggests active technology development aligned with durable LEO and sustainability themes over a 1 year+ horizon. Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision. Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction. |
| 84 | Dhruva Space lowweak | Opp 4 Risk 2 | Thesis: Among this screen, Dhruva Space has one of the stronger reviewed sources rationales: it is described as having received a government grant for Project Garud, a 500 kg-class satellite platform for constellation-scale missions, and later partnering with ICEYE on satellite systems and Earth observation services. If current, those items imply platform and partnership traction that could matter over a 1 year+ horizon. Why now: The reviewed sources references: and: in the membership rationale, suggesting relatively recent strategic developments, but the coverage report still shows zero evidence after recent evidence window, so timing confidence is limited. Caveats: Positive thesis relies on membership rationale, not available direct evidence. Partnership evidence cannot be expanded through relation propagation beyond what is explicitly stated. |
| 85 | EDGX lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence rationale indicates EDGX is a Belgian spacetech startup with a prior €2.3M seed round and an in-orbit demonstration of its STERNA AI computing system on SpaceX Transporter-16. If still current, in-orbit validation plus prior funding can support a longer-horizon commercialization opportunity. Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence. Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk. |
| 86 | Ellipsis Drive lowweak | Opp 4 Risk 3 | Thesis: Moderate opportunity on sparse evidence: the reviewed sources membership rationale describes Ellipsis Drive as addressing an Earth observation satellite-data processing bottleneck, with support from space agencies and target users including Earth observation firms. If accurate, that points to a software-layer position that could benefit over a 1 year+ adoption cycle. Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided. Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue. |
| 87 | Eta Space lowweak | Opp 4 Risk 2 | Thesis: Eta Space has reviewed sources support that its LOXSAT mission will demonstrate 11 cryogenic fluid management technologies in space and that the mission is launched by Rocket Lab for NASA, indicating real technology validation relevance for in-space fueling or orbital servicing over a 1 year+ horizon. Why now: The membership rationale specifically points to the LOXSAT mission demonstration as the current relevance driver, citing article: but the reviewed sources does not include the article or more detailed dated evidence fields. Caveats: Underlying article is not provided in the reviewed sources. Score is based on membership rationale summary rather than available direct evidence. Single-mission validation is weaker than broad commercial traction. |
| 88 | Firefly Aerospace lowweak | Opp 4 Risk 2 | Thesis: Firefly has a positive long-horizon lunar infrastructure angle because recent article context says NASA awarded it a Moon Base contract for MoonFall, a 2028 mission to transport four drones for Artemis-site surveying. Why now: A dated May 26, 2026 article puts a fresh NASA program win into the current evidence window, which can matter over a 1 year+ horizon even if revenue realization is later. Evidence
Caveats: Only one within the recent evidence window article is available. Evidence is supporting article context rather than stronger extracted direct events. Timing of mission realization is long-dated relative to the evidence window. |
| 89 | Hispasat lowweak | Opp 4 Risk 2 | Thesis: The reviewed sources membership rationale states Hispasat is part of the IRIS2 project and will manage the LEO shell. If current, that implies meaningful strategic positioning in a long-duration European satcom infrastructure program. Why now: The only timing clue is the membership rationale referencing article, but the underlying article summary and are not included in these reviewed sources. Recency beyond the batch month label is uncertain. Caveats: No representative article or is available in the reviewed sources despite the favorable rationale. Program-role evidence can be important, but without economics or milestones the opportunity case is incomplete. |
| 90 | Impulse Space lowweak | Opp 4 Risk 4 | Thesis: Membership rationale ties Impulse Space to a Pentagon deal for space-based interceptor prototypes and identifies orbital transfer vehicle relevance, which would be strategically meaningful over a 1 year+ horizon if confirmed with current evidence, but the reviewed sources does not load the underlying evidence or article summaries after recent evidence window, unavailable in reviewed sources). Why now: Why now is only medium because defense-space prototype work can matter over a 1 year+ horizon, but the reviewed sources' available evidence is empty after recent evidence window, preventing higher-conviction ranking. Caveats: No current evidence is provided for. No direct evidence remained after the recent evidence filter. Potential opportunity rests on membership rationale rather than available corroborated evidence. |
| 91 | MDA Space Ltd. lowweak | Opp 4 Risk 3 | Thesis: MDA Space shows some opportunity context from being identified as operating in in-orbit servicing and from an article saying it won a Radarsat replenishment satellite contract, which could support durable government-space demand if current. Why now: Why-now is weak because both available representative articles are undated, so current timing and whether these items remain incremental versus already absorbed is uncertain Evidence
Caveats: Both cited articles are undated; recency is uncertain. Support is weak and based on article context, not direct positive events. No material adverse evidence is available, but no strong current catalyst is validated either. |
| 92 | Modul8 lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence membership rationale says Modul8 is a spun-out space communications unit with $40m funding, lunar cellular network deployment, and Artemis spacesuit communications work. If still current, that is among the stronger long-horizon strategic opportunity setups in this screen, but the reviewed sources does not provide citeable direct evidence or article. Why now: Among sparse names, the stated combination of funding plus lunar communications program exposure could matter over 1 year+, but recency cannot be validated from served evidence. Caveats: The strongest claims are only in membership rationale and not backed by citeable -bearing evidence in the reviewed sources. No negative evidence does not equal low fundamental risk. |
| 93 | Momentus Inc lowweak | Opp 4 Risk 5 | Thesis: Membership rationale says Momentus secured a new commercial contract for its Vigoride-9 orbital service vehicle and identifies the company as an orbital service vehicle / orbital services platform business, which would support a real opportunity thesis for space logistics if current and corroborated. However, these reviewed sources have no direct evidence or article summaries after recent evidence window, so the opportunity score must stay modest (: and: unavailable in reviewed sources). Why now: Why now is medium because an orbital services contract can matter over a 1 year+ horizon, but the reviewed sources' post-recent evidence window evidentiary absence prevents stronger timing confidence. Caveats: No direct evidence remained after the recent evidence filter. |
| 94 | NEC Corporation lowweak | Opp 4 Risk 2 | Thesis: Membership rationale states NEC launched an Orbital Transfer Vehicle development project selected by JAXA and aims for Asia's first OTV deployment. That would be a credible long-horizon strategic opportunity if current, but the reviewed sources provide no available direct evidence or article summaries inside the recent evidence window to validate progress (: unavailable in reviewed sources). Why now: Why now is medium rather than weak because an OTV development project can be durable over 1 year+, but evidentiary support in the reviewed sources are thin after recent evidence window. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Current milestone timing is unverified in the reviewed sources. |
| 95 | NewOrbit Space mediummedium | Opp 4 Risk 4 | Thesis: NewOrbit Space has a plausible long-horizon opportunity because an article says it is developing satellites for very low Earth orbit and raised $18.5 million in a Series A round, suggesting both a differentiated technical focus and capital to pursue it. Why now: Why now is weaker than Aavuus because the article has no publication date. The reviewed sources explicitly says no is available and recency-sensitive claims should be treated cautiously., undated Evidence
Caveats: Evidence is supporting article context only, not direct structured positive event evidence. Publication date is unavailable; recency is uncertain. Single-article support only; no independent confirmation. |
| 96 | NorthStar Earth & Space lowweak | Opp 4 Risk 3 | Thesis: NorthStar Earth & Space appears strategically relevant to space domain awareness and may have public-market access or financing optionality via a SPAC path, but these reviewed sources provide only limited supporting article context and no strong in-window direct facts for business traction. Why now: The only dated evidence in this row is an April 27, 2026 article-level summary stating NorthStar Earth & Space plans to go public in a SPAC deal at a $300 million valuation. That may matter over a 1 year+ horizon, but the reviewed sources does not provide stronger company-specific direct evidence here. Evidence
Caveats: Coverage is extremely thin in this row: only one external article and no direct positive or negative dated events. The phase-2 rationale mentions a CAD$40M+ Royal Canadian Air Force contract, but that contract evidence is not directly surfaced in the available evidence fields for this output row, so it should not be elevated beyond the membership rationale. |
| 97 | Obruta Space Solutions lowweak | Opp 4 Risk 4 | Thesis: Obruta operates in a strategically attractive area: autonomous docking for on-orbit servicing and logistics, with stated use cases including inspection, orbital refueling, satellite life extension, debris removal, and orbital logistics. That gives a plausible long-horizon opportunity narrative if product or customer validation emerges. Why now: The only dated visible evidence is a company-site page with a May 20, 2026 describing the technology and target markets, which is relevant for strategic positioning but not enough to prove commercial inflection within the next year. Evidence
Caveats: Evidence is company-site descriptive context only. No third-party validation, financing, contract, or deployment evidence is shown. |
| 98 | Observable Space lowweak | Opp 4 Risk 4 | Thesis: Moderate opportunity based on the reviewed sources membership rationale that Observable Space was listed among notable space startup funding deals at $90 million. A funding round of that size can support growth over a 1 year+ horizon if deployed effectively. Why now: Why now is the funding mention tied to article ID: but the reviewed sources provide no, operating specifics, or additional corroborating evidence. Caveats: Funding alone is positive evidence but does not prove business quality. Article ID: is referenced without. |
| 99 | OMSPACE lowweak | Opp 4 Risk 4 | Thesis: The reviewed sources membership rationale says OMSPACE successfully launched a sounding rocket and plans an orbital launch vehicle by 2027 for small satellites. That suggests a real technical progression path if the company can convert suborbital progress into orbital capability over the next year-plus. Why now: The reviewed sources' rationale references article: for a successful sounding-rocket launch and a 2027 orbital-launch target, but the underlying article summary/ is not included here, limiting recency and sequence assessment. Caveats: Evidence is limited to a broad membership rationale without article detail. A sounding-rocket success is meaningfully earlier-stage than an orbital launch business. Risk and opportunity are both elevated relative to peers because the technology path is ambitious but still lightly evidenced. |
| 100 | Orbital lowweak | Opp 4 Risk 3 | Thesis: Orbital has modest evidence-backed opportunity because a dated within the recent evidence window article says it raised $5 million to fund an in-orbit computing demonstration next year and support initial work on its first purpose-built orbital compute satellite, Orbital-1, slated for 2028, indicating financing plus roadmap progress relevant to a 1 year+ horizon, June 10, 2026). Why now: The recency is relatively fresh: the is based on June 10, 2026, inside the 90-day recent evidence window, and it frames both new capital and a next-year demo as near-to-medium-term strategic milestones. Evidence
Caveats: All retained evidence is weak context supporting article context; there is no direct positive event/fact available. Same-article repeated rows are not independent confirmation. The opportunity case depends on an early-stage roadmap and financing announcement; commercial traction is not directly evidenced in retained rows. |
Risk view
Showing rows 241-260 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 241 | AEVEX Corp. lowweak | Opp 1 Risk 1 | Thesis: No direct negative evidence is available in the reviewed sources; the main limitation is insufficient company-specific proof of role, traction, or adversity. Why now: There is no reviewed sources-grounded catalyst or timing support for a 1 year+ thesis. The reviewed sources references article id: but provides no, quote, or retained evidence row. Caveats: Sector/SPAC mention is supporting article context and weaker than direct company-specific events or facts. No representative article summary or is present for direct citation. Low scores reflect sparse evidence, not a strong directional view. |
| 242 | Agnikul Cosmos lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is provided within the reviewed sources for the selected recent evidence window, so a negative thesis is also unsupported. Why now: Why now is unsupported because the reviewed sources show zero evidence after recent evidence filtering despite many articles considered; recency-specific business state cannot be established from the provided evidence. Caveats: Coverage debug shows zero evidence after recent evidence filtering. Membership rationale cannot substitute for cited directional evidence under the output rules. Absence of evidence is not positive or negative proof. |
| 243 | Airbus SE lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources does not provide material adverse company-specific evidence within the recent evidence window, so risk is low on reviewed sources evidence but not affirmatively cleared. Why now: There is no within the recent evidence window evidence available for Airbus; the only cited article is older context published March 4, 2025, outside the 90-day cutoff noted by the reviewed sources, so recency support is weak. Caveats: Coverage after recent evidence window is effectively empty: articles after recent evidence window is 0. The available Airbus article is contextual and outside the 90-day recent evidence window. Cohort membership does not establish attractiveness. |
| 244 | Alta Ares lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supportable because the retained reviewed sources contain no direct negative evidence after recent evidence window. Why now: Why now is weak: the reviewed sources show no retained evidence after recent evidence window, and the membership rationale says Alta Ares appears only in a broad funding roundup without enough company-specific detail. Caveats: Phase-2 membership rationale references: but no article summary or direct retained evidence is available here for factual use. The reviewed sources itself says company-specific detail is insufficient. |
| 245 | Altamira Technologies Corporation lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supportable because the reviewed sources does not provide direct negative evidence for Altamira in the scoring section. Why now: The phase2 rationale notes only that Parsons acquired Altamira and references defense/national security themes, but no citable evidence are provided here. Coverage data shows zero articles after recent evidence window and zero evidence available. Caveats: Ownership/acquisition context alone is not enough without direct evidence detail. No dated catalyst evidence is surfaced in the reviewed sources. |
| 246 | Amazon.com Inc. lowweak | Opp 1 Risk 1 | Thesis: No direct adverse space-related evidence is available in the reviewed sources for Amazon within the recent evidence window. Why now: No current catalyst can be established from the available evidence because post-recent evidence window evidence are absent. Caveats: Extremely large mention universe is not conviction. No usable evidence were available after recent evidence window. |
| 247 | AnduraX lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window negative evidence is available, so a risk thesis is not evidence-supported in these reviewed sources. Why now: There is no retained article or evidence row after the 90-day recent evidence window, so the reviewed sources does not establish a current catalyst or updated business state. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and: but no or retained summaries are provided here. Scores remain low because positive or negative direction cannot be grounded with citable retained evidence. |
| 248 | Angkasa-X Holdings Corp. lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window direct negative evidence is provided in the reviewed sources, so there is not enough support for a material adverse thesis either. Why now: There is no usable within the recent evidence window article evidence available for ranking; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency-sensitive judgment is not possible from these reviewed sources alone. Caveats: Reviewed evidence notes one considered article for membership support but zero article IDs after recent evidence window and zero available evidence after recent evidence window, so ranking is constrained by evidence absence rather than business absence. Membership rationale references article: but the reviewed sources does not provide the article or a retained within the recent evidence window evidence row for ranking use. |
| 249 | Antaris Inc. lowweak | Opp 2 Risk 1 | Thesis: No material adverse thesis is supported because no direct negative evidence are provided. Why now: Why now is weak: the only reviewed sources signal is the phase2 rationale mentioning a post-Series A portfolio reference tied to article, but no representative article summary or direct evidence row is included here to establish timing or business impact. Caveats: The cited Series A context appears only in phase2 rationale rather than in stronger scoring evidence fields. No product, customer, or execution evidence is provided. |
| 250 | Applied Aerospace & Defense Inc. lowweak | Opp 1 Risk 1 | Thesis: There is also insufficient material adverse evidence in the reviewed sources to support a negative thesis. The lack of direct evidence is uncertainty, not a demonstrated business risk. Why now: Why now is weak because the reviewed sources show zero evidence available after the 90-day recent evidence window cutoff date of March 29, 2026, so recency-based catalysts cannot be established from these reviewed sources. Caveats: No current evidence is provided for cited Evidence rows available after recent evidence window: 0. Mention as competition or IPO context is weaker than direct company event evidence. |
| 251 | ArianeGroup lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources provide no direct negative evidence, so no adverse thesis is supportable from this evidence set. Why now: The phase2 rationale references Ariane 6/Arianespace launch context for Amazon Kuiper, but relation/context evidence cannot be used as counterparty propagation and no direct evidence is exposed in the scoring fields. Coverage data shows zero articles after recent evidence window and zero evidence available. Caveats: Do not use context-only relation logic as direct thesis proof. No direct company-specific event evidence is included here. |
| 252 | Arxis, Inc. lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supported within the retained 90-day evidence window; there is also no direct negative evidence available for Arxis. Why now: Why now is unclear because coverage data shows 0 articles after recent evidence window and 0 evidence after recent evidence window, so there is no retained recent catalyst evidence in the reviewed sources. Caveats: Reviewed evidence cites membership support from, but no representative article is provided, so the underlying claim cannot be restated as direct scored evidence with. Coverage after recent evidence window is empty, limiting conviction. |
| 253 | Arxis Inc. lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supportable from the retained reviewed sources evidence because no direct negative evidence survived the 90-day recent evidence window. Why now: Why now is weak: the reviewed sources show zero evidence after recent evidence window for Arxis Inc., so there is no current catalyst or current business-state proof in the retained record. Caveats: Coverage after recent evidence window is empty for this company. Phase-2 membership rationale references support references including: but no article summary or quoted evidence is included in the retained reviewed sources, so it cannot be used for factual claims here. |
| 254 | Aselsan lowweak | Opp 1 Risk 1 | Thesis: No retained in-recent evidence window evidence supports a current adverse thesis. Why now: The reviewed sources retained zero evidence after the 90-day cutoff, so there is no current catalyst evidence for the 1 year+ ranking despite article-based membership context. Caveats: Membership rationale cites article, but no article summary or retained evidence row is available here. 24 articles were considered, but none remained after recent evidence filtering. |
| 255 | Astranis Space Technologies lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is available in the reviewed sources. Why now: No retained article or facts remain in the reviewed sources after recent evidence window, so timing and durability cannot be judged from local evidence. Caveats: Opportunity view depends on uncited membership rationale rather than retained evidence. No recency-confirmed direct evidence in reviewed sources. |
| 256 | Astro Digital lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is available. Risk remains low but non-zero because the company-specific operating picture is unestablished in retained evidence. Why now: No supported current catalyst. The reviewed sources explicitly warns this is counterparty context only, and coverage debug shows no retained evidence after recent evidence window. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Counterparty context should not be treated as strong propagation evidence. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 257 | Astrobiome Space lowweak | Opp 1 Risk 1 | Thesis: No material risk thesis is supportable from retained evidence in these reviewed sources because no direct negative rows survive the recent evidence window. Why now: There is no retained evidence showing a current contract milestone, financing event, or product progress inside the recent evidence window. Caveats: Phase-2 rationale says Astrobiome Space contracted Redwire for a commercial space greenhouse/ISS agriculture mission and cites: and: but no or summaries are available here. Coverage debug shows 6 articles considered and 0 after recent evidence window. Relationship context should not be propagated as stronger evidence without direct retained event/facts. |
| 258 | Astrolight lowweak | Opp 2 Risk 1 | Thesis: The lack of retained direct evidence creates uncertainty around current contract scope, deployment status, and commercialization durability; no explicit negative evidence is available. Why now: Why now is weak because the reviewed sources cites support article: in membership rationale, but no, article summary, or retained evidence are provided after the 90-day filter. Caveats: Potentially strong fundamentals are only referenced in membership rationale without citable article details. Coverage data shows zero articles after recent evidence window and zero evidence after recent evidence window. Private-company status also limits external validation in these reviewed sources. |
| 259 | Astrome lowweak | Opp 2 Risk 1 | Thesis: No reviewed sources evidence points to material adverse developments. The constraint is evidentiary thinness, so risk remains low but uncertain. Why now: Why now is weak because the support exists only in the phase-2 rationale; coverage data shows zero evidence after recent evidence window, so timing and durability of the funding support cannot be verified from local evidence. Caveats: No direct article or event evidence is available after recent evidence window. Government-support statement is not accompanied by a dated in-window source in the reviewed sources. Low confidence due to sparse evidence. |
| 260 | Atomos Space lowweak | Opp 2 Risk 1 | Thesis: No material adverse evidence is present in the reviewed sources. Risk remains low-scored only because evidence is sparse, not because risk is disproven. Why now: Why now is limited and recency is uncertain: the only retained evidence is undated supporting context, so it cannot establish a fresh catalyst, only background relevance, article date_basis: undated). Evidence
Caveats: The evidence is undated, and the reviewed sources explicitly says to treat undated external evidence as relevance context rather than recency proof. The retained rows are weak context and neutral polarity, not positive evidence. Same article repeated rows are not independent confirmation. |